NASDAQ:BCYC

Bicycle Therapeutics Stock News

Healthcare > Biotechnology

Buy BCYC

*Your capital is at risk

$4.11

-0.0600 (-1.44%)

At Close: Aug 10, 2026

Hedge Funds Are Buying Bicycle Therapeutics plc (BCYC)

10:46pm, Friday, 12'th Jun 2020

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investmen

Bicycle Therapeutics to Present at Upcoming Investor Conferences

10:59am, Wednesday, 27'th May 2020

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today annou

Bicycle Therapeutics to Present New Translational Research for BT5528 and Preclinical Data for Tumor-targeted Immune Cell Agonists at the AACR Virtual Annual Meeting II

10:59am, Friday, 15'th May 2020

Bicycle Therapeutics to Present Trials in Progress Poster for BT5528 at the 2020 American Society of Clinical Oncology Virtual Meeting

09:09pm, Wednesday, 13'th May 2020

Bicycle Therapeutics Announces Publication of BT5528 Mechanism of Action in AACR Journal Molecular Cancer Therapeutics

10:59am, Tuesday, 12'th May 2020

Growth Investors: Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%

01:32pm, Friday, 08'th May 2020

Celebrations may be in order for Bicycle Therapeutics plc (NASDAQ:BCYC) shareholders, with the analysts delivering a...

Bicycle Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

10:59am, Thursday, 07'th May 2020

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycles®) technology, today repor